New Data Suggests Experimental Drug KD025 May Help Treat Lupus

Kadmon Corporation, LLC issued a press release announcing preclinical data to be presented at FOCIS Thursday June 25 demonstrating the therapeutic potential of inhibiting ROCK2 (Rho-associated coiled-coil kinase 2) for lupus.

"ROCK2 inhibition represents an important approach to treat lupus, a painful, debilitating autoimmune disease with limited therapeutic options," said Peter Lipsky, M.D., Scientific Advisor, Alliance for Lupus Research and the Lupus Research Institute. "These data provide encouraging results that KD025 will be effective in treating lupus in the clinical setting."